JP2023525758A - Ａｋｔ３モジュレーターおよびその使用方法 - Google Patents

Ａｋｔ３モジュレーターおよびその使用方法 Download PDF

Info

Publication number
JP2023525758A
JP2023525758A JP2022567883A JP2022567883A JP2023525758A JP 2023525758 A JP2023525758 A JP 2023525758A JP 2022567883 A JP2022567883 A JP 2022567883A JP 2022567883 A JP2022567883 A JP 2022567883A JP 2023525758 A JP2023525758 A JP 2023525758A
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
akt3
aryl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022567883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525758A5 (cg-RX-API-DMAC7.html
Inventor
クレイフ，サミル
ムクルティチャン，ミカエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgiamune Inc
Original Assignee
Georgiamune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgiamune Inc filed Critical Georgiamune Inc
Publication of JP2023525758A publication Critical patent/JP2023525758A/ja
Publication of JP2023525758A5 publication Critical patent/JP2023525758A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Amplitude Modulation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022567883A 2020-05-08 2021-05-07 Ａｋｔ３モジュレーターおよびその使用方法 Pending JP2023525758A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063021797P 2020-05-08 2020-05-08
US63/021,797 2020-05-08
PCT/US2021/031372 WO2021226510A2 (en) 2020-05-08 2021-05-07 Akt3 modulators and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023525758A true JP2023525758A (ja) 2023-06-19
JP2023525758A5 JP2023525758A5 (cg-RX-API-DMAC7.html) 2024-05-16

Family

ID=78468492

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567883A Pending JP2023525758A (ja) 2020-05-08 2021-05-07 Ａｋｔ３モジュレーターおよびその使用方法

Country Status (12)

Country Link
US (1) US20230181563A1 (cg-RX-API-DMAC7.html)
EP (1) EP4146196A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023525758A (cg-RX-API-DMAC7.html)
KR (1) KR20230019109A (cg-RX-API-DMAC7.html)
CN (1) CN115956078A (cg-RX-API-DMAC7.html)
AU (1) AU2021269065A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022022327A2 (cg-RX-API-DMAC7.html)
CA (1) CA3182675A1 (cg-RX-API-DMAC7.html)
IL (1) IL297596A (cg-RX-API-DMAC7.html)
MX (1) MX2022014019A (cg-RX-API-DMAC7.html)
PH (1) PH12022553026A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021226510A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023524596A (ja) * 2020-05-08 2023-06-12 ジョージアミューン・インコーポレイテッド Ａｋｔ３モジュレーター
JP2023525757A (ja) * 2020-05-08 2023-06-19 ジョージアミューン・インコーポレイテッド Ａｋｔ３モジュレーター

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021212111A1 (en) * 2020-04-17 2021-10-21 Augusta University Research Institute, Inc. Compositions and methods for treating leukemia

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006524253A (ja) * 2003-04-24 2006-10-26 メルク　エンド　カムパニー　インコーポレーテッド Ａｋｔ活性の阻害剤
JP2010506856A (ja) * 2006-10-12 2010-03-04 スーパージェン， インコーポレイテッド Ｄｎａメチル化を調整するためのキノリン誘導体
JP2011500591A (ja) * 2007-10-12 2011-01-06 スーパージェン， インコーポレイテッド Ｄｎａメチル化を調整するためのキノリン誘導体
US20150343028A1 (en) * 2014-04-17 2015-12-03 Georgia Regents Research Institute, Inc. Methods of modulating immune responses by modifying akt3 bioactivity
US20170202829A1 (en) * 2016-01-15 2017-07-20 Augusta University Research Institute, Inc. Specific Akt3 Inhibitor and Uses Thereof Cross-Reference to Related Applications
US20170202956A1 (en) * 2016-01-15 2017-07-20 Augusta University Research Institute, Inc. Methods and Compositions for Inhibiting Akt3
WO2019005063A1 (en) * 2017-06-29 2019-01-03 Hewlett-Packard Development Company, L.P. PLANAR DISPLAY CONTIGU USABLE TO OBTAIN A ZONE PROVIDING PRIMARY DISPLAY AND A SECONDARY DISPLAY AREA

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03001256A (es) * 2000-08-11 2004-12-06 Vertex Pharma Inhibidores de p38.
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US7939546B2 (en) * 2007-10-12 2011-05-10 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
GB201207722D0 (en) * 2012-05-02 2012-06-13 Bergenbio As Method
EP3678666B1 (en) * 2017-09-07 2025-07-09 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006524253A (ja) * 2003-04-24 2006-10-26 メルク　エンド　カムパニー　インコーポレーテッド Ａｋｔ活性の阻害剤
JP2010506856A (ja) * 2006-10-12 2010-03-04 スーパージェン， インコーポレイテッド Ｄｎａメチル化を調整するためのキノリン誘導体
JP2011500591A (ja) * 2007-10-12 2011-01-06 スーパージェン， インコーポレイテッド Ｄｎａメチル化を調整するためのキノリン誘導体
US20150343028A1 (en) * 2014-04-17 2015-12-03 Georgia Regents Research Institute, Inc. Methods of modulating immune responses by modifying akt3 bioactivity
US20170202829A1 (en) * 2016-01-15 2017-07-20 Augusta University Research Institute, Inc. Specific Akt3 Inhibitor and Uses Thereof Cross-Reference to Related Applications
US20170202956A1 (en) * 2016-01-15 2017-07-20 Augusta University Research Institute, Inc. Methods and Compositions for Inhibiting Akt3
WO2019005063A1 (en) * 2017-06-29 2019-01-03 Hewlett-Packard Development Company, L.P. PLANAR DISPLAY CONTIGU USABLE TO OBTAIN A ZONE PROVIDING PRIMARY DISPLAY AND A SECONDARY DISPLAY AREA

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023524596A (ja) * 2020-05-08 2023-06-12 ジョージアミューン・インコーポレイテッド Ａｋｔ３モジュレーター
JP2023525757A (ja) * 2020-05-08 2023-06-19 ジョージアミューン・インコーポレイテッド Ａｋｔ３モジュレーター
JP7739334B2 (ja) 2020-05-08 2025-09-16 ジョージアミューン・インコーポレイテッド Ａｋｔ３モジュレーター

Also Published As

Publication number Publication date
US20230181563A1 (en) 2023-06-15
PH12022553026A1 (en) 2024-05-13
EP4146196A2 (en) 2023-03-15
AU2021269065A1 (en) 2022-12-15
KR20230019109A (ko) 2023-02-07
MX2022014019A (es) 2023-02-16
WO2021226510A9 (en) 2022-01-13
CA3182675A1 (en) 2021-11-11
WO2021226510A3 (en) 2021-12-16
WO2021226510A2 (en) 2021-11-11
IL297596A (en) 2022-12-01
BR112022022327A2 (pt) 2023-01-03
EP4146196A4 (en) 2024-06-26
CN115956078A (zh) 2023-04-11

Similar Documents

Publication Publication Date Title
US20250009735A1 (en) Specific akt3 activator and uses thereof
JP2021523110A (ja) 遺伝子発現のためのナノ粒子及びその使用
JP2024062999A (ja) ネクチン－４に対して特異的な二環式ペプチドリガンド
JP7622031B2 (ja) トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
JP7863349B2 (ja) ガンマデルタｔ細胞を刺激するための方法及び組成物
CN109414441A (zh) 治疗医学障碍的喹唑啉和吲哚化合物
AU2021269065A1 (en) Akt3 modulators and methods of use thereof
TW202142560A (zh) Ｇｌｐ－２衍生物之長效接合物
CN112654346A (zh) 生物分子包覆颗粒和薄膜及其用途
JP2024532810A (ja) 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法
JP2019534300A (ja) プログラム細胞死リガンド１の腸管発現
CA3140649A1 (en) Metabolite delivery for modulating metabolic pathways of cells
TW202132334A (zh) Ｃｘｃｒ４拮抗劑肽
HK40084846A (en) Akt3 modulators and methods of use thereof
CN118786207A (zh) 经修饰的细胞及其用途
RU2815372C2 (ru) Специфический активатор akt3 и его применение
US12115190B2 (en) IRF-4 engineered T cells and uses thereof in treating cancer
TW202220974A (zh) 用於調節ａｋｔ３的方法及組合物
WO2024145365A2 (en) Compositions for the diagnosis, treatment, prevention, and alleviation of neurodegenerative and autoimmune disorders
HK40033083A (en) Specific akt3 activator and uses thereof
HK40033083B (en) Specific akt3 activator and uses thereof
WO2023197014A2 (en) Combination therapy comprising pd-l1 knockout nk cell and anti-pdl1 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260513